aTyr Pharma translates tRNA synthetase biology into new therapies for fibrosis and inflammation.

aTyr Pharma

aTyr Pharma | 5,595 followers on LinkedIn. aTyr is a biotherapeutics company engaged in the development of innovative medicines based on novel biology. | aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. 

The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.

Chief Business Officer at Scribe Therapeutics

Svetlana Lucas

Ashlee Dunston

Gregory Solz, RQAP-GCP, CQM, CQA

Leslie Nangle

We released our third quarter 2024 financial results and corporate update today. To read the full earnings press release, click here: https://bit.ly/3CeWihI

Today we announced that the company will present at several upcoming investor conferences scheduled to take place in November and December 2024. In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. For more information, visit: https://bit.ly/40lgGb8

Today we announced that Sanjay S. Shukla, M.D., M.S., President and CEO, will present a corporate overview at the upcoming LD Micro Main Event XVII on October 29th at 9:00am PDT in Los Angeles, CA. For more information, please visit: https://bit.ly/3NlJkkK

We are pleased to announce that our lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis will be featured in the Best of CHEST Journals session today at the CHEST 2024 Annual Meeting. Dr. Daniel A. Culver, Chair of the Division of Pulmonary Medicine at Cleveland Clinic, will discuss data from the Phase 1b/2a study that were previously published in the CHEST journal and a post hoc analysis of the study that was recently published in the European Respiratory Society. For more information, please visit: https://bit.ly/3ByJgvg

Today we announced the publication of a post hoc analysis of the Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis in the European Respiratory Journal. The publication reports positive findings when analyzing time-to-first relapse and relapse rate for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups. These findings further demonstrate the efficacy of efzofitimod, and we believe we are on the cusp of a paradigm shift in the treatment for sarcoidosis, where patients may have the opportunity to receive a clinically validated treatment option that can help reduce or avoid steroid-related toxicity. The publication, entitled, “Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis,” is available on the Journal’s website and at: https://lnkd.in/gkH5NeEW . For more information, read here: https://bit.ly/47SDCju #sarcoidosis #pulmonarysarcoidosis #efzofitimod

As we close out Pulmonary Fibrosis Awareness Month, we would like to thank all of the organizations and individuals who worked to educate and generate awareness of this serious and often debilitating condition where there is scarring, or fibrosis, of the lungs. At aTyr, we will continue to support the pulmonary fibrosis (PF) community by working to develop efzofitimod as a potential treatment for those living with pulmonary sarcoidosis and SSc-ILD, two forms of interstitial lung disease (ILD) that can result in progressive fibrosis of the lungs. To learn more, visit www.atyrpharma.com . #PFAM #PulmonaryFibrosis #InterstitialLungDisease #PulmonarySarcoidosis #SScILD

Join aTyr’s President and CEO, Dr. Sanjay S. Shukla, today at 1:55pm EDT as he participates in a Fireside Chat at the 2024 Cantor Global Healthcare Conference to discuss our clinical development program for efzofitimod in interstitial lung disease. For more information on how to join, click here: https://bit.ly/3TyRsll .

Today is ILD Day, which is an important opportunity to bring awareness to interstitial lung disease (ILD), a group of rare, immune-mediated disorders that can cause progressive fibrosis, or scarring, of the lungs. aTyr is proud to support the ILD community by working to develop efzofitimod as a potential new treatment for those living with forms of ILD, including pulmonary sarcoidosis and SSc-ILD. Learn more about ILD Day here: https://bit.ly/47xtuwL . #ILDDay #InterstitialLungDisease #PulmonarySarcoidosis #SScILD

Today we announced that we will participate in several upcoming investor conferences scheduled to take place in September. Join us at the Wells Fargo Healthcare Conference, the H.C. Wainwright 26th Annual Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference. For more information, including on how to access webcasts of the events, read here: https://bit.ly/46XgGPD

We released our second quarter 2024 financial results and corporate update today. To read the full earnings press release, click here: https://bit.ly/3yDp61Y #ATYR

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

COM:ATYRPHARMA

aTyr Pharma

Last Close

1.85

04/06 20:00

Market Cap

131.12M

Beta: -

Volume Today

267.89K

Avg: -

Filings Not Available